論文

査読有り
2014年6月

Immunohistochemical evaluation of O-6-methylguanine DNA methyltransferase (MGMT) expression in 117 cases of glioblastoma

NEUROPATHOLOGY
  • Masaya Miyazaki
  • ,
  • Hiroshi Nishihara
  • ,
  • Shunsuke Terasaka
  • ,
  • Hiroyuki Kobayashi
  • ,
  • Shigeru Yamaguchi
  • ,
  • Tamio Ito
  • ,
  • Yuuta Kamoshima
  • ,
  • Shin Fujimoto
  • ,
  • Sadao Kaneko
  • ,
  • Masahito Katoh
  • ,
  • Nobuaki Ishii
  • ,
  • Hiromi Mohri
  • ,
  • Mishie Tanino
  • ,
  • Taichi Kimura
  • ,
  • Shinya Tanaka

34
3
開始ページ
268
終了ページ
276
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1111/neup.12091
出版者・発行元
WILEY-BLACKWELL

Temozolomide (TMZ) is an oral alkylating agent which is widely used in the treatment of glioblastoma (GBM) and is composed of astrocytic and/or oligodendroglial tumors, and the evaluation of O6-methylguanine DNA methyltransferase (MGMT) expression is important to predict the response to TMZ therapy. In this study, we conducted immunohistochemical analysis of 117 cases of Japanese GBM including 19 cases of GBM with oligodendroglioma component (GBMO), using a scoring system for quantitative evaluation of staining intensity and proportion of MGMT, and performed survival analysis of these patients. Immunohistochemically, 55 cases (47%) were positive for MGMT with various intensities and proportions (total score (TS)2), while 62 cases (53%) were negative (TS=0). The distribution of MGMT expression pattern was not affected by any clinicopathological parameters such as the histological subtype (GBM vs. GBMO), age and gender. The survival analysis of these patients revealed that the minimal expression of MGMT (TS2) was a significant unfavorable prognostic factor (P<0.001) as well as resectability (P=0.004). Moreover, multivariate analysis showed that minimal MGMT expression in GBM was the most potent independent predictor for progression free survival (P<0.001) and also overall patient survival (P<0.001). This is the first report employing the scoring system for both staining intensity and proportion to evaluate immunohistochemical MGMT expression in GBM. In addition, our results emphases the clinicopathological values of the immunohistochemical approach for MGMT expression in glioma patients as a routine laboratory examination.

Web of Science ® 被引用回数 : 17

リンク情報
DOI
https://doi.org/10.1111/neup.12091
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/24397721
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000337591300007&DestApp=WOS_CPL
ID情報
  • DOI : 10.1111/neup.12091
  • ISSN : 0919-6544
  • eISSN : 1440-1789
  • PubMed ID : 24397721
  • Web of Science ID : WOS:000337591300007

エクスポート
BibTeX RIS